-
Annexin V Workflows for Apoptosis Assays
2026-09-04
Turn phosphatidylserine externalization into a practical cell-death readout with recombinant Annexin V. Its unlabeled format supports both custom conjugation for apoptosis assays and competition-binding experiments, giving researchers flexibility beyond a single fluorescent endpoint.
-
Tamsulosin: From Receptor Precision to Translation
2026-09-04
A mechanistic and strategic guide to using Tamsulosin in GPCR signaling, smooth muscle, and urological research while connecting assay design with translational evidence.
-
Ceftolozane Sulfate: Assay Workflows and PK/PD
2026-09-03
Ceftolozane sulfate supports a practical research pipeline spanning broth microdilution, time-kill analysis, resistance surveillance, and translational PK/PD modeling. This guide shows how to distinguish intrinsic ceftolozane activity from combination-drug effects while improving assay consistency against Pseudomonas aeruginosa and selected Enterobacterales.
-
Latrunculin A: Reliable Actin Assay Design
2026-09-03
This scenario-based guide explains how Latrunculin A, SKU B7555, can improve interpretation of cell viability, morphology, motility, and cytoskeletal assays. It connects documented concentration and handling parameters with recent evidence linking actin–myosin II networks to viral proliferation.
-
Hsa_circ_0001944, FXR/TLR4, and Ferroptosis in LX-2 Cells
2026-09-02
The 2025 Toxics study identifies hsa_circ_0001944 as a regulatory node connecting FXR, TLR4, ferroptosis, and collagen formation in nickel oxide nanoparticle-exposed LX-2 hepatic stellate cells. Its pharmacological and genetic experiments suggest that enhancing FXR or hsa_circ_0001944, or inhibiting TLR4, can reduce collagen deposition while restoring ferroptosis-associated features.
-
Chlorpromazine HCl: Dopamine and Endocytosis
2026-09-02
Chlorpromazine HCl is a phenothiazine dopamine receptor antagonist used in psychotic disorder research and neuropharmacology studies. Product data and a peer-reviewed cell-infection model support its use as both a dopaminergic probe and a pharmacological perturbation of clathrin-mediated endocytosis, with important assay-specific limitations.
-
B7H3×CD3 BiTE mRNA-LNPs for Antitumor Therapy
2026-09-01
Huang and colleagues developed an ionizable lipid nanoparticle system carrying mRNA that encodes a B7H3×CD3 bispecific T-cell engager. Their results indicate that intravenous delivery can generate substantial in vivo BiTE expression, extend exposure, and produce durable antitumor activity in hematologic malignancy and melanoma models.
-
BFH772 (VEGFR2 inhibitor): Workflow Guide
2026-09-01
BFH772 is a selective VEGFR2 kinase research compound for testing VEGFR2-dependent signaling and angiogenesis-related phenotypes when controlled small-molecule inhibition is required. Its water insolubility, defined selectivity profile, and limited solution stability make solvent control, concentration verification, and matched controls essential.
-
T-5224: AP-1, Ferroptosis, and Assay Strategy
2026-08-31
T-5224, a selective C-Fos/AP-1 inhibitor, connects inflammatory transcriptional control with ferroptosis-related signaling in new multiple myeloma research. This article translates that finding into practical assay decisions for arthritis research, osteoclastogenesis, and pathway validation.
-
FITC Goat Anti-Rabbit IgG (H+L) Antibody Workflow
2026-08-31
Build sensitive immunofluorescence, flow cytometry, and fluorescent tissue-staining workflows around a fluorescein-conjugated secondary antibody. This practical guide translates lycopene–DON intestinal barrier research into assay design, controls, optimization, and troubleshooting decisions.
-
ISRIB and Accelerated Forgetting in Epilepsy
2026-08-30
A 2025 Molecular Neurobiology study identifies integrated stress response activation as a mechanistic contributor to both natural forgetting and seizure-associated accelerated forgetting in mice. Its retention-interval experiments show that repeated ISRIB treatment preserves established recognition memories, while a single administration does not alter retrieval, highlighting memory maintenance rather than recall as the intervention window.
-
PLGA Nano-Adjuvant for Intestinal IgA in Chicks
2026-08-29
The reference study develops PEI-LSP-RA-PLGA, a layered PLGA nanoparticle adjuvant designed to combine sustained antigen presentation with intestinal immune targeting. In chicks receiving an inactivated H9N2 vaccine, the formulation enhanced systemic IgG, intestinal IgA, immune-cell responses, and intestinal tissue characteristics while implicating CCR9/CCR6, Toll-like receptor, NOD-like receptor, and IgA-production pathways.
-
Temozolomide in ATRX-Stratified Glioma Assays
2026-08-28
Temozolomide is a small-molecule alkylating agent that can do more than induce cytotoxicity. This guide explains how to use ATRX status, DNA damage readouts, and combination design to improve interpretation in glioma research and DNA repair mechanism research.
-
SB525334 for TGF-beta1 Receptor Studies
2026-08-28
SB525334 enables selective ALK5 interrogation in fibrosis, renal disease, and wound-healing assays without treating pathway activation as universally beneficial. This guide translates a diabetic foot ulcer study into practical inhibitor workflows, controls, readouts, and troubleshooting decisions.
-
Dual-Action Inhibitors Reprogram p38α Dephosphorylation
2026-08-27
The reference preprint shows that selected kinase inhibitors can do more than occupy the p38α active site: they can expose the activation-loop phospho-threonine and accelerate its removal by the phosphatase WIP1. By combining biochemical dephosphorylation assays with X-ray crystallography, the study introduces a structure-based strategy for improving kinase inhibitor potency and specificity.